Key Takeaways
- After 14 years of research and 22,000 survey responses, polycystic ovary syndrome (PCOS) is renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its hormonal and metabolic nature.
- The name change, announced at the 8th European Congress of Endocrinology and published in The Lancet, aims to reduce misdiagnosis and improve treatment by shifting focus away from ovarian cysts.
- A large study co‑authored by Helena Teede found no higher rate of abnormal ovarian cysts in women with PMOS compared with the general population.
- Diagnostic criteria remain unchanged (irregular/absent ovulation, elevated androgen, ≥20 antral follicles on ultrasound), but future guidelines may de‑emphasize ultrasound for cyst detection.
- PMOS is linked to infertility, insulin resistance, type 2 diabetes, hypertension, cardiovascular disease, and mental‑health challenges, affecting roughly 170 million women worldwide.
- Patient advocates and clinicians welcome the rename, noting it validates lived experiences and encourages a holistic, lifespan‑approach to care.
- An international awareness campaign will support adoption of the new term, with inclusion in the 2028 International Classification of Diseases (ICD‑11).
Overview of the Renaming Initiative
The condition previously known as polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). This change follows 14 years of extensive research, incorporating over 22,000 survey responses from patients, clinicians, and researchers worldwide. The announcement was made at the 8th European Congress of Endocrinology in Prague and simultaneously published in the prestigious journal The Lancet. Led by Helena Teede, director of the Monash Centre for Health Research Implementation, the initiative seeks to correct a longstanding mischaracterization of the disorder and to improve diagnostic accuracy and therapeutic outcomes for the estimated 170 million women affected globally.
Research Foundations and Survey Scope
Teede’s team conducted a multi‑year, multinational effort that combined epidemiological studies, clinical trials, and qualitative interviews. The 22,000 survey responses captured a broad spectrum of experiences, from adolescent symptom onset to menopausal metabolic manifestations. This wealth of data allowed researchers to identify patterns that the former name failed to encapsulate, particularly the syndrome’s pervasive endocrine and metabolic disturbances. The rigorous methodology underpins confidence that the renamed entity reflects the current scientific consensus on the condition’s pathophysiology.
Why the Old Name Was Misleading
Professor Teede described the term “polycystic ovary syndrome” as “very inaccurate,” noting that it reduced a complex, lifelong condition to a superficial focus on ovarian cysts. Historically, the name directed clinical attention toward the ovaries, inadvertently sidelining other critical domains such as insulin resistance, lipid abnormalities, and mental‑health symptoms. By emphasizing cysts, the label fostered misconceptions that the disorder was primarily a reproductive issue, leading to under‑recognition of its systemic risks and delayed interventions for many patients.
Introducing Polyendocrine Metabolic Ovarian Syndrome (PMOS)
The new designation, polyendocrine metabolic ovarian syndrome, explicitly highlights the disorder’s dual endocrine and metabolic dimensions. “Polyendocrine” signals involvement of multiple hormone pathways—including androgen excess, insulin dysregulation, and adrenal contributions—while “metabolic” underscores the heightened risk for glucose intolerance, dyslipidemia, and cardiovascular disease. Teede argued that this nomenclature will help clinicians recognize PMOS as a systemic endocrine disorder rather than an isolated ovarian pathology, fostering more comprehensive assessment and management strategies.
Study Findings on Ovarian Cysts
A pivotal component of the renaming effort was a large study co‑authored by Terhi Piltonen, which examined ovarian cyst prevalence in women diagnosed with PCOS versus unaffected controls. Contrary to the implication of the former name, the research demonstrated that women with PMOS do not exhibit a higher rate of abnormal ovarian cysts than the general population. This finding challenges the cyst‑centric view and supports the rationale for de‑emphasizing ultrasound‑based cyst detection as a diagnostic cornerstone.
Diagnostic Criteria Remain Unchanged
Although the name has shifted, the diagnostic framework for PMOS retains the classic Rotterdam criteria: patients must present with at least two of the following—irregular or absent ovulation, clinical or biochemical signs of hyperandrogenism (e.g., hirsutism, acne, alopecia), and poly‑ovarian morphology defined as ≥20 antral follicles on ovarian ultrasound. Teede stressed that these thresholds continue to identify the syndrome accurately; however, the evidence suggesting no excess cyst formation may prompt future guideline revisions that lessen the diagnostic weight of ultrasonographic cyst counts.
Implications for Ultrasound Use
Given the absence of a cystic excess, experts anticipate that upcoming clinical guidelines may refine the role of pelvic ultrasound in PMOS assessment. While imaging will still be valuable for evaluating ovarian morphology and ruling out other pathologies, its primary purpose may shift from cyst counting to assessing follicular activity and endometrial health. This nuanced approach aims to reduce unnecessary testing, lower patient anxiety, and direct resources toward metabolic and hormonal evaluations that better reflect disease burden.
Broader Health Impacts
PMOS extends far beyond reproductive concerns. Women with the syndrome face elevated prevalence of central obesity, insulin resistance, and dyslipidemia, which collectively increase the long‑term risk of type 2 diabetes, hypertension, and cardiovascular events such as heart attacks and strokes. Moreover, the condition is strongly associated with mental‑health challenges, including depression, anxiety, and diminished quality of life. Recognizing these multisystem effects is essential for delivering holistic care that addresses both immediate symptoms and long‑term wellness.
Patient Voices on the Name Change
Advocate Lorna Berry, who experienced symptoms as a teenager but was not diagnosed until age 32, welcomed the rename, noting that a more scientifically accurate term would have prompted earlier, curiosity‑driven questioning from clinicians rather than simplistic advice to “starve myself.” Berry emphasized that reframing PMOS as a hormonal disorder encourages providers to consider the syndrome when patients present with fluctuating hormones, weight changes, skin issues, or mood disturbances. Similarly, Hannah Bambra, a 34‑year‑old living with PMOS, described the name change as validating her experience of being seen as a whole person, not merely a reproductive problem, and expressed hope that it will shift medical thinking toward comprehensive care.
General Practitioner Perspective on Missed Diagnoses
Magdalena Simonis, a GP and women’s‑health expert from the University of Melbourne, highlighted that many women are identified only during attempts to conceive, leaving those without fertility goals undiagnosed and deprived of early intervention. She warned that untreated PMOS can manifest later in life with insulin resistance and onset diabetes, underscoring the need for vigilance across the lifespan. Simonis urged clinicians to listen attentively to presentations such as weight gain, menstrual irregularities, hirsutism, acne, or ovulatory dysfunction, and to consider PMOS in roughly one‑in‑eight women exhibiting these signs.
Lifelong Nature and Variable Presentations
Teede reiterated that PMOS is a lifelong condition whose clinical picture evolves with age. Younger patients often struggle with acne, menstrual irregularities, and infertility; mid‑life individuals may confront worsening metabolic syndrome and fertility challenges; older women may present primarily with insulin resistance, type 2 diabetes, or cardiovascular risk factors. This variability reinforces the importance of viewing PMOS through a lifespan lens, ensuring that monitoring and treatment adapt to changing hormonal and metabolic needs over decades.
Awareness Campaign and Future Implementation
To facilitate global adoption, Teede’s team has launched an international awareness and education initiative targeting healthcare professionals, policymakers, and the public. The campaign aims to disseminate the new terminology, elucidate its clinical relevance, and promote integrated care pathways. The renamed entity is slated for inclusion in the 2028 revision of the International Classification of Diseases (ICD‑11), which will standardize coding, improve epidemiological tracking, and support resource allocation for PMOS‑focused research and services.
Through these concerted efforts, the shift from PCOS to PMOS promises to enhance diagnostic precision, broaden therapeutic horizons, and ultimately improve the health and wellbeing of millions of women worldwide.